Recursion Pharmaceuticals, INC Form 4 insider transactions

Blake Borgeson, a Director of Recursion Pharmaceuticals, Inc., sold 50,000 shares of common stock on October 6, 2026 for $4.84 per share.

Robert Hershberg, a Director of Recursion Pharmaceuticals, Inc., sold 25,000 shares of common stock on October 6, 2026 for $5.00 per share.

Zavain Dar, a Director of Recursion Pharmaceuticals, Inc., received 4,607 shares of common stock on October 1, 2026.

Dean Y Li, a Director of Recursion Pharmaceuticals, Inc., received 3,378 shares of common stock on October 1, 2026.

Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc., reported a transaction in 5,396 shares of common stock on September 15, 2026.

Najat Khan, CEO and President and a Director of Recursion Pharmaceuticals, Inc., sold 22,408 shares of common stock on September 8, 2026 for $3.52 per share.

Blake Borgeson, a Director of Recursion Pharmaceuticals, Inc., sold 30,000 shares of common stock on September 1, 2026 for $3.34 per share.

Najat Khan, CEO and President and a Director of Recursion Pharmaceuticals, Inc., reported a transaction in 80,498 shares of common stock on August 17, 2026.

David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc., reported a transaction in 26,657 shares of common stock on August 17, 2026.

Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc., reported a transaction in 25,018 shares of common stock on August 17, 2026.

Blake Borgeson, a Director of Recursion Pharmaceuticals, Inc., sold 30,000 shares of common stock on August 4, 2026 for $3.25 per share.

Blake Borgeson, a director at Recursion Pharmaceuticals, Inc., has reported the sale of 40,000 shares of Class A Common Stock.

Dar Zavain, a Director at Recursion Pharmaceuticals, received a stock grant under the company's Outside Director Compensation Policy.

Dean Y. Li, a Director at Recursion Pharmaceuticals, received a stock grant of 3,747 shares of Class A Common Stock on July 1, 2026.

Recursion Pharmaceuticals CFO Ben R. Taylor disposed of 5,396 shares to satisfy tax obligations related to restricted stock units.

Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock via a pre-arranged 10b5-1 plan.

Recursion Pharmaceuticals CEO Najat Khan sold 23,588 shares of Class A Common Stock under a pre-arranged trading plan.

Director Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals (RXRX) at $3.54 per share via a Rule 10b5-1 plan.

Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals common stock under a pre-arranged 10b5-1 trading plan.

Director Christopher Gibson of Recursion Pharmaceuticals reported a transaction involving Class A Common Stock, executed under a Rule 10b5-1 trading plan.

Chief Scientific Officer David Hallett disposed of 26,657 shares of Recursion Pharmaceuticals to satisfy tax obligations.

CEO Najat Khan disposed of 62,701 shares of Recursion Pharmaceuticals to satisfy tax obligations related to restricted stock units.

Recursion Pharmaceuticals CFO Ben Taylor disposed of 25,018 shares to satisfy tax obligations related to restricted stock units.

Director Christopher Gibson reported the net settlement of 22,821 shares of Class A Common Stock for tax obligations.

Director Christopher Gibson executed a conversion and sale of Class A Common Stock pursuant to a Rule 10b5-1 trading plan.

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported a transaction involving Class A Common Stock under a Rule 10b5-1 trading plan.

Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock via a Rule 10b5-1 trading plan.

Recursion Pharmaceuticals, Inc. reports a transaction by its Chief Financial Officer, Ben R. Taylor, involving Class A Common Stock.

Director Christopher Gibson has sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock for $3.10 per share, totaling $124,000, as part of a pre-arranged trading plan.

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported a transaction involving 30,000 shares of Class A Common Stock on April 7, 2026, executed under a Rule 10b5-1 trading plan.